Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gils

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Journal of Molecular Biology|March 25, 2000
Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivationH Nar, M Bauer, J M Stassen, et al.
Alimentary Pharmacology & Therapeutics|February 7, 2017
Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control studyS Van Steenbergen, S Bian, S Vermeire, et al.
Alimentary Pharmacology & Therapeutics|July 6, 2011
Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assayN Vande Casteele, C Breynaert, S Vermeire, et al.
Journal of Thrombosis and Haemostasis : JTH|March 31, 2016
Evaluation of and recommendation for the nomenclature of the CPB2 gene product (also known as TAFI and proCPU): communication from the SSC of the ISTHJ H Foley, P Y Kim, D Hendriks, et al.
Alimentary Pharmacology & Therapeutics|April 18, 2013
Letter: dry blood spots for anti-TNF treatment monitoring in IBDN Vande Casteele, S Brecx, P Declerck, et al.
Alimentary Pharmacology & Therapeutics|August 10, 2016
Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experienceT Billiet, I Cleynen, V Ballet, et al.
Journal of Thrombosis and Haemostasis : JTH|April 22, 2004
Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresisA H C Guimarães, M M Barrett-Bergshoeff, A Gils, et al.
Journal of Thrombosis and Haemostasis : JTH|August 2, 2007
Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stabilityE Ceresa, M De Maeyer, A Jonckheer, et al.
Journal of Thrombosis and Haemostasis : JTH|December 21, 2013
Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo applicationM L V Hendrickx, M Zatloukalova, G Hassanzadeh-Ghassabeh, et al.
The British Journal of Dermatology|April 21, 2019
Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasisN Van den Berghe, E De Keyser, R Soenen, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Journal of Molecular Biology|March 25, 2000
Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivationH Nar, M Bauer, J M Stassen, et al.
Alimentary Pharmacology & Therapeutics|February 7, 2017
Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control studyS Van Steenbergen, S Bian, S Vermeire, et al.
Alimentary Pharmacology & Therapeutics|July 6, 2011
Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assayN Vande Casteele, C Breynaert, S Vermeire, et al.
Journal of Thrombosis and Haemostasis : JTH|March 31, 2016
Evaluation of and recommendation for the nomenclature of the CPB2 gene product (also known as TAFI and proCPU): communication from the SSC of the ISTHJ H Foley, P Y Kim, D Hendriks, et al.
Alimentary Pharmacology & Therapeutics|April 18, 2013
Letter: dry blood spots for anti-TNF treatment monitoring in IBDN Vande Casteele, S Brecx, P Declerck, et al.
Alimentary Pharmacology & Therapeutics|August 10, 2016
Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experienceT Billiet, I Cleynen, V Ballet, et al.
Journal of Thrombosis and Haemostasis : JTH|April 22, 2004
Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresisA H C Guimarães, M M Barrett-Bergshoeff, A Gils, et al.
Journal of Thrombosis and Haemostasis : JTH|August 2, 2007
Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stabilityE Ceresa, M De Maeyer, A Jonckheer, et al.
Journal of Thrombosis and Haemostasis : JTH|December 21, 2013
Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo applicationM L V Hendrickx, M Zatloukalova, G Hassanzadeh-Ghassabeh, et al.
The British Journal of Dermatology|April 21, 2019
Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasisN Van den Berghe, E De Keyser, R Soenen, et al.
Pageof 6